Products for Research Use Only

Safinamide

CAT: 0804-HY-70057-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-70057-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Safinamide is a potent, selective, and reversible monoamine oxidase B (MAO-B) inhibitor (IC50=0.098 μM) over MAO-A (IC50=580 μM) [1]. Safinamide also blocks sodium channels and modulates glutamate (Glu) release, showing a greater affinity at depolarized (IC50=8 μM) than at resting (IC50=262 μM) potentials. Safinamide has neuroprotective and neurorescuing effects and can be used for the study of parkinson disease, ischemia stroke etc.al[2][3].
CAS Number
133865-89-1
Product Name Alternative
FCE 26743; EMD 1195686
UNSPSC
12352005
Hazard Statement
H302, H319
Target
Monoamine Oxidase
Type
Reference compound
Related Pathways
Neuronal Signaling
Applications
Neuroscience-Neuromodulation
Field of Research
Neurological Disease
Assay Protocol
https://www.medchemexpress.com/Safinamide.html
Concentration
10mM
Purity
99.89
Solubility
DMSO : ≥ 100 mg/mL
Smiles
O=C([C@@H](NCC1=CC=C(OCC2=CC(F)=CC=C2)C=C1)C)N
Molecular Formula
C17H19FN2O2
Molecular Weight
302.34
Precautions
H302, H319
References & Citations
[1]Leonetti F, et al. Solid-phase synthesis and insights into structure-activity relationships of safinamide analogues as potent and selective inhibitors of type B monoamine oxidase. J Med Chem, 2007, 50 (20), 4909-4916.|[2]C Caccia, et al.Safinamide: from molecular targets to a new anti-Parkinson drug. Neurology. 2006 Oct 10;67 (7 Suppl 2) :S18-23.|[3]Michele Morari, et al. Safinamide Differentially Modulates In Vivo Glutamate and GABA Release in the Rat Hippocampus and Basal Ganglia.J Pharmacol Exp Ther. 2018 Feb;364 (2) :198-206.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
MAO-A; MAO-B
Citation 01
Ecotoxicol Environ Saf. 2023 Aug 7:262:115284.|Behav Brain Res. 2024 Feb 29:459:114787.

Alternative Products